References
- Zm Y, Ab K, Abdelatif D, et al., Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1): 73–84.
- European Association for the Study of the Liver (EASL). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.
- Chalasani N, Younossi Z, Je L, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–357.
- Mendez-Sanchez N, Vc C-R, Ol R-P, et al. New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci. 2018;19(7):2034.
- Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50(4):364–377.
- Eslam M, Pn N, Sk S, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209.
- Angulo P, Kleiner DE, Dam-Larsen S, et al., Liver fibrosis, but no other histologic features, is associated with long–term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2): 389–97.e10.
- Liu K, Vw W, Lau K, et al. Prognostic value of controlled attenuation parameter by transient elastography. Am J Gastroenterol. 2017;112(12):1812–1823.
- Romeo S, Kozlitina J, Xing C, et al., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12): 1461–1465.
- Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17(1):40–52.
- Alexander M, Ak L, Van Der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnose in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17(1):95.
- Younossi ZM, Tampi RP, Racila A, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. U.S. Diabetes Care 2020;43(2):283–289.
- Cusi K. A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): knowledge gaps and future directions. Liver Int. 2020;40(Suppl S1):82–88.
- Lonardo A, Nascimbeni F, Mantovani A. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352.
- Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564–568.